4.7 Article

Evitar: designing anti-viral RNA therapies against future RNA viruses

Journal

BIOINFORMATICS
Volume 38, Issue 9, Pages 2437-2443

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/bioinformatics/btac144

Keywords

-

Funding

  1. National Institutes of Health [R01GM116855, R01GM138856, R33CA225863, R33CA246711]

Ask authors/readers for more resources

This study developed the Evitar pipeline for designing anti-viral siRNAs and CRISPR Cas13a gRNA sequences. Time simulations using known coronavirus genomes showed that pre-designed siRNAs and gRNAs could target SARS-CoV-2 and other viruses. In vitro experiments confirmed the potential of designed siRNAs to suppress SARS-CoV-2 viral sequences. The results support the utility of Evitar in pre-designing therapeutics against future RNA virus outbreaks.
Motivation: The coronavirus disease 2019 (COVID-19) pandemic has highlighted the threat of emerging respiratory viruses and has exposed the lack of availability of off-the-shelf therapeutics against new RNA viruses. Previous research has established the potential that siRNAs and RNA-targeting CRISPR have in combating known RNA viruses. However, the feasibility and tools for designing anti-viral RNA therapeutics against future RNA viruses have not yet been established. Results: We develop the Emerging-Virus-Targeting RNA (Evitar) pipeline for designing anti-viral siRNAs and CRISPR Cas13a guide RNA (gRNA) sequences. Within Evitar, we develop Greedy Algorithm with Redundancy and Similarity-weighted Greedy Algorithm with Redundancy to enhance the performance. Time simulations using known coronavirus genomes deposited as early as 10 years prior to the COVID-19 outbreak show that at least three SARS-CoV-2-targeting siRNAs are among the top 30 pre-designed siRNAs. In addition, among the top 19 pre-designed gRNAs, there are three SARS-CoV-2-targeting Cas13a gRNAs that could be predicted using information from 2011. Before-the-outbreak design is also possible against the MERS-CoV virus and the 2009-H1N1 swine flu virus. Designed siRNAs are further shown to suppress SARS-CoV-2 viral sequences using in vitro reporter assays. Our results support the utility of Evitar to predesign anti-viral siRNAs/gRNAs against future viruses. Therefore, we propose the development of a collection consisting of roughly 30 pre-designed, safety-tested and off-the-shelf siRNA/CRISPR therapeutics that could accelerate responses to future RNA virus outbreaks.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available